Publication:
Anticipating the side effects of benznidazole: HLA-B*35 and patch test

Simple item page
dc.contributor.authorVázquez, Cristina
dc.contributor.authorGarcía-Vázquez, Elisa
dc.contributor.authorCarrilero, Bartolomé
dc.contributor.authorMuro, Manuel
dc.contributor.authorSánchez-Guerrero, Inmaculada
dc.contributor.authorGonzález López, Rosana
dc.contributor.authorFranco, Fuensanta
dc.contributor.authorSegovia, Manuel
dc.contributor.departmentMedicina
dc.date.accessioned2024-06-19T10:28:19Z
dc.date.available2024-06-19T10:28:19Z
dc.date.issued2024-04-14
dc.description©2024 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ . This document is the Accepted version (author`s homepage), article in press that will appear in Enfermedades Infecciosas y Microbiología Clínica. To access the final edited and published work see https://doi.org/10.1016/j.eimc.2024.04.006es
dc.description.abstractABSTRACT: Introduction: Treatment of Chagas disease frequently causes distress to patients due to a high incidence of adverse effects. Different preemptive tests have been researched to prevent these effects and to allow focus to be given to certain predisposed patients. Benznidazole is the most prescribed Chagas disease treatment in Spain. In this work, we analyzed the genetic markers HLA-B*35 allele group and HLA-B*35:05 allele specifically, as well as an allergy patch test, as benznidazole’s most frequent adverse effects are cutaneous. Methods: HLA-B intermediate-resolution genotyping was performed followed by a high-resolution level analysis. Cutaneous allergies were tested using strips impregnated with a mixture of benznidazole and placed on the upper back of patients before starting treatment. Results: In our sample of more than 400 patients, there was almost no relationship between any kind of side effect and either of the HLA-B alleles studied. The patch testing was quickly discarded as a preemptive test due to its low sensitivity (16.7%). Conclusion: In conclusion, we were unable to replicate and corroborate genetic markers identified by other groups and there is currently no test that can anticipate the adverse effects of benznidazole, therefore, more investigation should be carried out in this field.es
dc.description.abstractRESUMEN: Introducción: El tratamiento de la enfermedad de Chagas causa frecuentemente angustia a los pacientes debido a su alta incidencia de reacciones adversas. Se han investigado algunos test para anticiparnos y poner especial foco en aquellos pacientes susceptibles de sufrir estos efectos. Benznidazol es el tratamiento más prescrito para la enfermedad de Chagas en España. En este trabajo hemos analizado la familia alélica HLA-B*35, y específicamente HLA-B*35:05, así como un test alérgico epicutáneo (patch test), teniendo en cuenta que el efecto adverso más frecuente son reacciones cutáneas. Métodos: El HLA-B de los pacientes se genotipó con resolución intermedia y después se analizó mediante alta resolución. Antes del tratamiento, se testó una posible hipersensibilidad cutánea mediante tiras impregnadas con una solución de benznidazol adheridas en la parte alta de la espalda de los pacientes. Resultados: En nuestra muestra de más de 400 pacientes no se detectó relación entre ningún tipo de efecto adverso y ningún alelo de HLA-B estudiado. La prueba de patch test se canceló al poco de empezar el estudio debido a su baja sensibilidad (16,7%).es
dc.formatapplication/pdfes
dc.format.extent5es
dc.identifier.citationEnfermedades Infecciosas y Microbiología Clínica xxx (xxxx) xxx–xxx
dc.identifier.doihttps://doi.org/10.1016/j.eimc.2024.04.006
dc.identifier.issnPrint: 0213-005X
dc.identifier.issnElectronic: 1578-1852
dc.identifier.urihttp://hdl.handle.net/10201/142418
dc.languageenges
dc.publisherElsevieres
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-avance-resumen-anticipating-side-effects-benznidazole-hla-b35-S0213005X24002386es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBenznidazolees
dc.subjectHLAes
dc.subjectHLA-B*35:05es
dc.subjectChagas diseasees
dc.subjectPatch testes
dc.subjectTrypanosoma cruzies
dc.subjectBenznidazoles
dc.subjectEnfermedad de Chagases
dc.titleAnticipating the side effects of benznidazole: HLA-B*35 and patch testes
dc.title.alternativeAnticipándonos a los efectos adversos del benznidazol: HLA-B*35 y patch testes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Anticipating the side effects of benznidazole....pdf
Size:
393.27 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos